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Summary Human solid tumours are composed of a significant proportion of hypoxic cells, i.e. cells with oxygen levels lower than those of
normal tissues. Tumour hypoxic cells have been shown to have a negative impact on the response of solid tumours to radiation therapy and
chemotherapy. However, these low cellular oxygen levels can be exploited by a drug that is specifically activated to a cytotoxic metabolite at
these low levels. Tirapazamine is a novel bioreductive agent with selective cytotoxicity to hypoxic tumourcells, irrespective of their p53 status
or apoptotic response, and acts synergistically with cisplatin. This potentiation is dependent on an interaction that can only take place in a
hypoxic environment, resulting in a significant sensitization of the cells to cisplatin cell killing, with no increase in the systemic toxicity of
cisplatin. Thus, the low cellular oxygen levels common in solid tumours can be turned from disadvantage to advantage using the hypoxia-
selective cytotoxic drug tirapazamine.
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Tumour hypoxia is common and often associated with resistance
to chemotherapy and radiation therapy (Moulder and Rockwell,
1984; Grau and Overgaard, 1988; Vaupel et al, 1989, 1995;
Teicher et al, 1990). In our recent work (Adam et al, 1998),
37 tumours from patients with squamous cell cancer of the head
and neck were measured using a polarographic needle electrode
('PO2 Histograph', Eppendorf, Hamburg) to determine the range
of oxygen levels within the tumours. When the median values for
the tumours were compared with those of normal subcutaneous
tissue taken from each of the patients, it was found that approxi-
mately 70% of the tumours had median oxygen levels lower than
the lowest median value found in normal tissue (Figure 1). Indeed,
no normal tissues had oxygen levels below 20 mmHg, whereas
approximately 90% ofthe tumours did.
EXPLOITING TUMOUR HYPOXIA
It has been clearly demonstrated that tumour hypoxia causes resis-
tance to radiation therapy and probably also to chemotherapy
(Bush et al, 1978; Grau and Overgaard, 1988). In a trial carried
out by Nordsmark and colleagues (1996), local regional tumour
control ofhead and neck cancer treated with radiation therapy was
assessed as a function of tumour oxygenation. Patients who
responded well were those whose tumours included a high propor-
tion ofoxygenated cells.
No clinical trials have been carried out to investigate whether or
not a similar effect occurs with chemotherapy. However, there is
good preclinical evidence to suggest that the presence of hypoxic
cells in tumour masses is a determining factor in terms of resis-
tance to chemotherapy. As the level of oxygen in cells further
away from the blood vessels decreases, the proliferation rate ofthe
cells also decreases (Tannock, 1968; Rodriguez et al, 1994), which
would lead to drug resistance. Also, the concentration of any drug
would be lower in the cells further away from the blood vessels
because of the reactivity of the drug with cells. In addition, it
has been discovered recently that various genes are selectively
expressed under hypoxic conditions, and that hypoxia appears to
confer selectivity for mutant p53 (Graeber et al, 1996). As muta-
tions in p53 are widely believed to lead to resistance against many
anticancer drugs as a result of the loss of the p53-dependent apo-
ptotic response, this is a further reason that tumour cell hypoxia is
likely to have a negative effect on the response of tumour cells to
radiation therapy or chemotherapy. Accordingly, a drug that is
only activated by hypoxic tumourcells to become cytotoxic would
be tumour specific, and this is the mode of action of the benzo-
triazine di-N-oxide tirapazamine.
The selective toxicity oftirapazamine to hypoxic cells has been
studied by a number of investigators. Figure 2 shows an example
from our work using mouse SCCVII cells in vitro (Brown, 1993).
The cells were exposed to tirapazamine for 1 h. In oxygenated
cells, the drug concentration required to achieve the same level of
toxicity as that of the hypoxic cells was 300-fold higher. Other
studies have confirmed the results ofthis study, using different cell
lines, with the majority showing hypoxic cytotoxicity ratios of
between 15 and 150 (Brown and Siim, 1996).
The mechanism of this preferential cytotoxicity towards
hypoxic cells is via a reductase enzyme, which intracellularly
reduces tirapazamine to a highly toxic free radical. This free
radical then kills the tumour cell by damaging the DNA. In the
presence ofoxygen, however, the free radical is readily oxidized to
the non-toxic parent molecule. The lower toxicity under aerobic
conditions is due to the fact that the superoxide radical that is
formed is less harmful to the cell than the tirapazamine radical.
OVERCOMING MUTANT P53
Tirapazamine kills hypoxic tumour cells, irrespective of their p53
status or apoptotic response. Mouse embryo fibroblasts taken from
wild-type mice (p53+/+) were compared with fibroblasts taken from
p53 knockout mice (p53-/-) (Wouters and Brown, unpublished
data). No difference was found in clonogenic cell survival between
the two types offibroblast afterhypoxic exposure to tirapazamine for
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Figure 1 Median oxygen levels of normal subcutaneous tissue (A)
compared with two different nodes of squamous cell cancer of the head and
neck showing a well (B) and poorly (C) oxygenated tumour
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Figure 3 Cellular interaction between tirapazamine and cisplatin in vitro
(Brown and Wang, 1998)
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Figure 2 Preferential toxicity of tirapazamine on hypoxic mouse cells
in vitro (Brown, 1993). HCR, hypoxic cytotoxicity ratio
h. We have also compared the sensitivity of non-small-cell lung
cancer cell lines with wild-type or mutant p53 to tirapazamine under
hypoxic conditions and found no difference in sensitivity to tirapaza-
mine between the cells that were mutant and those that were wild-
type in p53 (Wang and Brown, unpublished data).
Figure 4 Potentiation of cisplatin cell kill by tirapazamine of the cells of
RIF-1 tumours in vivo (Dorie and Brown, 1993)
scheduling of the two drugs. Given together, the effects of tira-
pazamine and cisplatin are additive. However, if the tirapazamine
is given first, with cisplatin given 1-3 h later, there is a resulting
synergy in a number of cell lines. An example with NIH3T3
mouse cells is shown in Figure 3 (Brown and Wang, 1998).
Potentiation of cisplatin toxicity has also been shown in mouse
tumours (Dorie and Brown, 1993). As shown in Figure 4 with the
transplanted RIF-1 tumour, when tirapazamine and cisplatin were
given together, an additive effect was seen. However, when tira-
pazamine was given 2-3 h before cisplatin, the level of cell kill
increased by a factor of 103-104. Despite this tumour potentiation,
tirapazamine had no apparent effect on cisplatin toxicity to the
animal. This is of considerable clinical significance, and early
clinical trials have confirmed this lack of enhanced cisplatin
toxicity to normal tissues (Rodriguez et al, 1996).
POTENTIATING CISPLATIN CYTOTOXICITY
Tirapazamine under hypoxic conditions has been found to
potentiate cisplatin toxicity in a tumour-specific manner. This is a
potentially beneficial clinical effect, which depends on careful
CONCLUSIONS
The low oxygen levels frequently found in a significant percentage
of solid tumours can be turned from disadvantage to advantage
using the hypoxic-cell-selective cytotoxic drug tirapazamine,
British Journal of Cancer (1998) 77(Supplement 4), 12-14
a1)
a)
A
20 -
18 -
16 -
14 -
12 -
10 -
8-
6-
4-
2-
0
10°
lo-'
cu 2 10-2 0
Ca
0c
C:
u)
10-4
10-5
--n . . flnnnn,,n----
V
.
0 Cancer Research Campaign 199814 JMBrown
which is the first such drug to enter clinical trials. Preclinical
studies have shown a tumour-specific enhancement of radiation
(Brown and Lemmon, 1990) and cisplatin and carboplatin tumour
cell kill with tirapazamine.
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